← Back to Search

Protein Kinase Inhibitor

15 mg AKB-9778 BID for 84 days for Central Retinal Vein Occlusion

Phase 2
Waitlist Available
Led By Peter A Campochiaro, MD
Research Sponsored by Aerpio Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 84 days
Awards & highlights
No Placebo-Only Group

Summary

Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.

Eligible Conditions
  • Central Retinal Vein Occlusion
  • Retinal Vein Occlusion

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~84 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 84 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual acuity in subjects with RVO

Side effects data

From 2019 Phase 2 trial • 167 Patients • NCT03197870
15%
Diabetic retinal oedema
9%
Influenza
7%
Nasopharyngitis
7%
Urinary tract infection
7%
Retinal neovascularisation
5%
Localized infection
5%
Eye pain
5%
Vitreous haemorrhage
5%
Sinusitis
4%
Hordeolum
4%
Gastroenteritis viral
4%
Cellulitis
4%
Dry eye
4%
Bronchitis
2%
Cerebrovascular accident
2%
Osteomyelitis
2%
Upper respiratory tract infection
2%
Pneumonia
2%
Mallory-Weiss syndrome
2%
Tooth abscess
2%
Skin infection
2%
Vitreous floaters
2%
Hyphaema
2%
Visual impairment
2%
Retinal cyst
2%
Diabetic gangrene
2%
Perineal abscess
2%
Vomiting
2%
Hypotension
2%
Anaemia
2%
Prostate cancer
2%
Glaucoma
2%
Ocular hyperaemia
2%
Macular oedema
2%
Vitreous detachment
2%
Contusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Razuprotafib 15mg Daily
Placebo Twice Daily
Razuprotafib 15mg Twice Daily

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 15 mg AKB-9778 BID for 84 daysExperimental Treatment1 Intervention
Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Razuprotafib
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Aerpio TherapeuticsLead Sponsor
8 Previous Clinical Trials
697 Total Patients Enrolled
Peter A Campochiaro, MDPrincipal InvestigatorWilmer Eye Institute
10 Previous Clinical Trials
802 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top